Celltrion

Galux and Celltrion join forces to accelerate next-gen autoimmune drug development Korea Biomedical Review23:49Galux AI IT

Celltrion, Galux partner on multispecific antibody drugs The Korea Herald01:12Galux AI IT

Celltrion’s Omlyclo debuts in Brazil -- first-ever Xolair biosimilar hits Latin America Korea Biomedical Review02:48Xolair Brazil Latin America

Celltrion launches first Xolair biosimilar in Brazil The Korea Herald00:52Xolair Brazil Latin America

Celltrion accelerates Europe rollout of Xolair biosimilar Korea Biomedical Review02:25Novartis Pharma Omlyclo

Celltrion scores EU line extension OK for Omlyclo in 300 mg pre-filled syringe Korea Biomedical Review02:21Novartis Pharma Omlyclo

Celltrion ramps up US plant upgrade to preempt tariff risks The Korea Herald00:18

Celltrion to invest 4 trillion won to expand domestic facilities Korea JoongAng Daily01:34

Celltrion to commit ₩4 tril. to manufacturing and R&D expansion in Korea over next 3 years Korea Biomedical Review20:02

Once a biosimilar pure play, Celltrion reloads with Lilly plant and obesity pill in push to rival Samsung Biologics Korea Biomedical Review23:19Eli Lilly Pharma Top Tech Brands

Celltrion secures Health Canada go-ahead for Eylea biosimilar Pharmaceutical Technology11:33Canada

Celltrion ADC candidate gets FDA fast track designation The Korea Herald01:00FDA Business (US) Pharma

Latest News

In the last 7 days

Galux And Celltrion Enter Strategic Partnership To Co-Develop Next-Generation Multispecific… Drugs Discovery Online05:33 4-Dec-25

Celltrion ADC candidate gets FDA fast track designation The Korea Herald01:00 4-Dec-25

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the… PR Newswire (Press Release)19:44 2-Dec-25

Celltrion, Galux partner on multispecific antibody drugs The Korea Herald01:12 2-Dec-25

Galux and Celltrion join forces to accelerate next-gen autoimmune drug development Korea Biomedical Review23:49 1-Dec-25

Celltrion secures major US PBM listings for denosumab biosimilars, accelerating early market penetration Korea Biomedical Review21:54 30-Nov-25

In the last month

Celltrion secures Health Canada go-ahead for Eylea biosimilar Pharmaceutical Technology11:33 28-Nov-25

Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea®… Business Wire (Press Release)19:03 27-Nov-25

Celltrion’s Remsima IV approved by EC in liquid form Pharmafile12:28 27-Nov-25

Celltrion’s Omlyclo debuts in Brazil -- first-ever Xolair biosimilar hits Latin America Korea Biomedical Review02:48 27-Nov-25

Celltrion launches first Xolair biosimilar in Brazil The Korea Herald00:52 27-Nov-25

Celltrion's Zymfentra shows consistent efficacy across all Crohn’s disease sites in new post-hoc analysis Korea Biomedical Review00:54 26-Nov-25

Celltrion accelerates Europe rollout of Xolair biosimilar Korea Biomedical Review02:25 25-Nov-25

TriOar inks $356 million platform tech transfer and joint development deal with Celltrion Korea Biomedical Review21:54 19-Nov-25

Celltrion to widen US manufacturing reach with $478M investment at former Lilly plant FiercePharma11:33 19-Nov-25

Celltrion to invest 4 trillion won to expand domestic facilities Korea JoongAng Daily01:34 19-Nov-25

Celltrion ramps up US plant upgrade to preempt tariff risks The Korea Herald00:18 19-Nov-25

Celltrion to invest 4 tln won to expand domestic facilities Yonhap News Agency23:24 18-Nov-25

Once a biosimilar pure play, Celltrion reloads with Lilly plant and obesity pill in push to rival Samsung Biologics Korea Biomedical Review23:19 18-Nov-25

Celltrion scores EU line extension OK for Omlyclo in 300 mg pre-filled syringe Korea Biomedical Review02:21 18-Nov-25

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg Business Wire (Press Release)21:54 17-Nov-25

Celltrion to commit ₩4 tril. to manufacturing and R&D expansion in Korea over next 3 years Korea Biomedical Review20:02 16-Nov-25

Kaigene partners with Celltrion for novel antibody therapeutics in autoimmune diseases for $736 M BioSpectrum Asia03:34 12-Nov-25

Celltrion cleared to buy US Eli Lilly plant The Korea Herald00:34 11-Nov-25

Fierce Pharma Asia—Lilly's AI drug design deal; Celltrion's autoimmune pact; China to lift… FiercePharma09:50 7-Nov-25

view more headlines

4 Dec 05:33

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.